Literature DB >> 23091338

The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.

Carole Alison Chrvala.   

Abstract

Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents.

Entities:  

Year:  2012        PMID： 23091338      PMCID： PMC3474424     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  37 in total

1.  Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials.

Authors:  M Roach; J Lu; M V Pilepich; S O Asbell; M Mohiuddin; R Terry; D Grignon; M Mohuidden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

Review 2.  New and emerging agents for the treatment of castration-resistant prostate cancer.

Authors:  Celestia S Higano; E David Crawford
Journal:  Urol Oncol       Date:  2011 Nov-Dec       Impact factor: 3.498

3.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

4.  A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

Authors:  K J Pienta; E I Fisher; M A Eisenberger; G M Mills; J W Goodwin; J A Jones; S R Dakhil; E D Crawford; M H Hussain
Journal:  Prostate       Date:  2001-03-01       Impact factor: 4.104

Review 5.  Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

6.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.

Authors:  Louis Potters; Carol Morgenstern; Emil Calugaru; Paul Fearn; Anup Jassal; Joseph Presser; Edward Mullen
Journal:  J Urol       Date:  2008-05       Impact factor: 7.450

9.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544
View more
  1 in total

Review 1.  Update on the challenges and recent advances in cancer immunotherapy.

Authors:  Gianfranco Baronzio; Gurdev Parmar; Irina Zh Shubina; Valter Cassutti; Sergio Giuli; Marco Ballerini; Mikhail Kiselevsky
Journal:  Immunotargets Ther       Date:  2013-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.